Schlieren (Zurich), Switzerland, August 12 , 2015 – Cytos Biotechnology Ltd. (SIX:CYTN) ( " Cytos " ) announced today that it executed an exclusive licen se agreement in the field of oncology granting Checkmate Pharmaceuticals LLC, Cambridge, MA, USA ("Checkmate") exclusive access to Cytos’ clinically validated product candidate CYT003 as well as its VLP platform and to technology related to oligonucleotide synthesis (Press release, Cytos Biotechnology, AUG 12, 2015, View Source [SID1234516802]). Cytos may receive up to USD 90 million in development milestones and may receive up to double – digit royalties on net sales from successfully developed products. "We are excited about the potential of our immunologically active VLP platform in the field of immune – oncology and believe that Checkmate is well positioned to advance treatment options for patients with cancer ," commented Christian Itin, Chairman and CEO of Cytos

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!